Healthcare stocks advanced 1.6% at midday Monday.
The S&P 500 and the Nasdaq Composite index both closed 0.5% higher on Friday, reaching record highs on Wall Street.
BlinkLab (ASX:BB1) obtained institutional review board approval from US-based clinical research oversight provider WIRB-Copernicus Group for the main study phase of its US FDA 510(k) diagnostic trial evaluating the BlinkLab Dx 1 technology, a smartphone-based autism assessment tool.
On the flip side, the materials sector struggled, falling 1%, amid profit-taking from iron ore producers.
Mineral Resources (ASX:MIN) completed the sale of its Yilgarn iron ore assets and operations in Western Australia to Yilgarn Iron Investments, transferring ownership and all associated environmental and rehabilitation responsibilities. Yilgarn Iron will assume all environmental, closure, and rehabilitation liabilities, while the company retains the gold and lithium rights on the associated tenements.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。